Page 1669 - Clinical Small Animal Internal Medicine

Index 1607

treatment 725 canine distemper virus 851–852 biology of cancer and cancer
VetBooks.ir gamma‐glutamyl transferase (GGT) see cirrhosis 706, 710–711 canine myocardial disease
genetics 1205–1211
chronic enteropathies 627–637
gallops 255, 270–271, 273
computed tomography 469,
259, 265
enzyme markers of liver disease
gas exchange efficiency 378–379 471–472, 472 chronic enteropathies 627–628,
gastric adenocarcinomas 1284 dysbiosis 621–626 634–635
gastric dilation 483, 483 general imaging deregulating cellular
gastric dilation‐volvulus (GDV) principles 469–473 energetics 1209–1210
acute poisoning 442 imaging contrast agents and enabling replicative
gastritis and gastric ulceration 550 pharmacoradiology 469 immortality 1205–1206
gastrointestinal imaging intraluminal contrast agents evading growth suppressors 1206
483–485, 484 470–471, 470 genome instability and
motility disorders 567 magnetic resonance imaging mutation 1207
pulmonary thromboembolism 318 469, 472 inducing angiogenesis 1208–1209
gastric inhibitory polypeptide (GIP) motility disorders 563–581 liver disease 653
49–50 radiography 469–471, 470 metabolic bone
gastric lavage 442 scintigraphy 472–473 diseases 1526–1527
gastrinoma 1215–1216, 1300 septic shock 424 nonmelanoma skin cancers 1353
gastritis and gastric ulceration shock 405, 406 pituitary‐dependent
547–555 trauma and burns 453 hyperadrenocorticism 50–51, 51
ancillary diagnostic testing 553 ultrasonography 471 resisting cell death 1206–1207
cirrhosis 706, 710–711 see also endoscopy; individual sustaining proliferative
clinicopathologic examination 552 anatomical components signaling 1209
diagnostic approach 552–553 gastrointestinal motility and tumor promoting
endoscopy 513, 518–519, 519 integrity 351 inflammation 1207–1208
epidemiology 549–550 gastrointestinal perforation 486–487 GERD see esophagitis/gastroesophageal
etiology/pathophysiology gastrointestinal stromal tumors (GIST) reflux disease
547–549, 548 1283–1285, 1287–1290, 1291 GES see gastroesophageal sphincter
gastrointestinal imaging 487, 488 gastroprotectants 693, 701, 1216 gestational diabetes 93
histopathology 552–553 gastroscopy 517–519, 519, GFR see glomerular filtration rate
history and clinical signs 550–551 552–553, 1284 GH see growth hormone
imaging 552 GCS see Glasgow Coma Scale GHRH see growth hormone‐releasing
normal gastric mucosal barrier GDV see gastric dilation‐volvulus hormone
function 547 gelatins 360 GI see gastrointestinal
prognosis 555 gels 1398, 1469 giant migrating contractions
treatment 553–554, 554 generalizability see external validity (GMC) 574
gastroduodenal ulceration 644 generalized deep pyoderma giardiasis 1018–1019
gastroenteritis 550–551 1465, 1465 diagnosis 1018
gastroesophageal intussusception 479 generalized esophageal dilation epidemiology 1018
gastroesophageal junction 479, 479 475–476, 475–476 etiology/pathophysiology 1018
gastroesophageal reflux 478, generalized hepatomegaly 661, 662 history and clinical signs 1018
560–561 generalized systemic tumors 686 signalment 1018
gastroesophageal sphincter general proprioceptive (GP) treatment and prognosis
(GES) 563–564 system 732–734, 816 1018–1019
gastrography 480–483 general somatic afferent (GSA) gingival hyperplasia 534–535
gastrointestinal eosinophilic sclerosing neurons 735 gingivitis 533–536, 535
fibroplasia 491 general somatic efferent (GSE) GIP see gastric inhibitory polypeptide
gastrointestinal (GI) bleeding neurons 735 GIST see gastrointestinal stromal
gastrointestinal imaging 489 general visceral efferent (GVE) tumors
hypoadrenocorticism 82, 85 neurons 737 Glasgow Coma Scale (GCS)
paraneoplastic syndromes 1220 genetics and genetic testing 751–752, 752, 758
gastrointestinal (GI) tract activating invasion and see also Modified Glasgow Coma
acute poisoning 437, 438, metastasis 1210 Scale
441–443 avoiding immune destruction 1208 gliomas 1267